Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas

Area of Science:

• Genomics and Molecular Oncology
• Cancer Genetics
• Thyroid Cancer Research

Background:

• Aneuploidy in papillary thyroid carcinomas (PTCs) is linked to a poorer prognosis.
• Limited genetic studies exist for aneuploid PTCs, hindering understanding of their aggressive behavior.
• Investigating genetic alterations in aneuploid PTCs is crucial for developing targeted therapies.

Purpose of the Study:

• To comprehensively analyze the genetic landscape of aneuploid PTCs.
• To identify specific genetic alterations and molecular pathways associated with aggressive PTC behavior.
• To explore potential therapeutic targets for aneuploid PTCs.

Main Methods:

• Comparative genomic hybridization (CGH) array analysis on 17 aneuploid PTCs.
• BRAF and RAS mutational status assessment.
• Screening for RET/PTC1 and RET/PTC3 rearrangements.
• Gene expression profiling and validation using TaqMan and immunohistochemistry.

Main Results:

• CGH revealed multiple non-random chromosomal abnormalities in aneuploid PTCs.
• BRAFV600E and RAS mutations were detected in 41.2% and 33% of cases, respectively.
• No RET/PTC1 or RET/PTC3 rearrangements were found.
• Overexpression of HMGA2 indicated a loss of transcriptional control.
• Gene expression correlated with mutational status (e.g., cMET and FN1 overexpression in BRAF+ cases).
• DDR2 overexpression and downregulation of immune/inflammatory/adhesion genes were associated with disease progression and metastasis.

Conclusions:

• Aneuploid PTCs exhibit a distinct genetic profile characterized by chromosomal aberrations and altered gene expression.
• Specific molecular alterations, such as HMGA2 overexpression and DDR2 dysregulation, are implicated in aggressive tumor behavior.
• Identified molecular targets may pave the way for novel, more effective therapeutic strategies against aneuploid PTCs.